The 3-year survival was markedly higher in the high-lncRNA-ANRIL group and high SOX9 group than in the low-lncRNA-ANRIL group and low SOX9 group, suggesting that lncRNA-ANRIL and SOX9 are related to the prognosis of patients with glioma. This evidence concerns the gene CDKN2B-AS1 and central nervous system cancer.